<DOC>
	<DOCNO>NCT00002189</DOCNO>
	<brief_summary>To determine response rate , median time tumor progression , qualitative quantitative toxicity reversibility toxicity patient advanced refractory AIDS-associated Kaposi 's sarcoma ( KS ) administer 3-hour infusion paclitaxel every 14 day . To evaluate clinical benefit paclitaxel patient population evaluate self-reported response Symptom Distress Scale document evaluate change lymphedema , pain disfigure facial lesion .</brief_summary>
	<brief_title>Paclitaxel Advanced Refractory Kaposi 's Sarcoma ( AIDS-KS ) : A Phase II Trial Paclitaxel From Baker Norton Pharmaceuticals</brief_title>
	<detailed_description>Patients treat paclitaxel intravenously every 2 week 10 course . Patients achieve complete response receive 2 additional course achieve partial response stabilization , continue therapy progression .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Antineoplastic Agents , Phytogenic</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion Criteria Patients must : Microscopically confirm diagnosis KS associate HIV systematic therapy medically indicate presence least one following : A . &gt; = 25 mucocutaneous ( mouth skin ) lesion . B. Symptomatic visceral involvement . C. Symptomatic lymphedema ( pain ) . Minimum 5 clearly measurably cutaneous lesion physical exam measurable disease Xray , CT MRI . Failed least one systemic chemotherapy regimen . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Less 2 week since major surgery . Serious uncontrolled infection . NOTE : Must rule thorough workup patient unexplained fever , night sweat , involuntary weight loss 10 % normal weight . Leukopenia . Thrombocytopenia . Patients follow prior condition exclude : History angina myocardial infarction within past 6 month . Second degree third degree atrioventricular block without pacemaker . Congestive heart failure ( poorly control ) . History prior malignancy except : Completely excise situ , carcinoma cervix nonmelanomatous skin cancer . Curatively treated malignancy evidence disease least 5 year . Prior Medication : Excluded : Prior taxane therapy . Required : At least one systemic chemotherapy regimen fail maintain significant benefit . NOTE : Intralesional chemotherapy regimen consider prior chemotherapy . At least 2 week since last dose prior systemic chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1998</verification_date>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Treatment Outcome</keyword>
	<keyword>Antineoplastic Agents , Phytogenic</keyword>
</DOC>